Track DaVita Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

DaVita Inc. DVA · Stock Open DaVita Inc. in new tab

174.56 USD
P/E
14.05
EPS
13.21
P/B
-19.90
ROE
96.79
Beta
0.86
Target Price
222.29 USD
DaVita Inc. logo

DaVita Inc.

🧾 Earnings Recap – Q3 2026

DaVita shares fell 3.0% after earnings, with higher-than-forecast technology investment in U.S. dialysis weighing on full-year financial performance. The transcript also points to limited near-term financial contribution from expanded HD: management expects no material net impact on adjusted operating income in 2026 or 2027.

  • Q3 adjusted operating income was **$561 million** and adjusted EPS was **$3.82**.
  • Technology investment was higher than forecast heading into the year and is a drag on full-year performance; management expects its growth to decelerate going forward.
  • IKC was above plan in Q3, and the company said it was on track to outperform its original full-year guidance.
  • Expanded HD pilots covered **150 centers** and more than **10,000 patients**; adoption among clinically eligible pilot patients exceeded **90%**. National rollout was due to begin the following week, with most eligible patients expected to transition in November.
  • Management expects expanded HD’s positive impact from lower mortality and higher volume growth to begin in the **second half of 2028**; it cited a goal of returning to **2% or greater volume growth by 2029**.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 1, 2027
P/E14.05
EPS13.21
Book Value-9.32
Price to Book-19.90
Debt/Equity1189.57
% Insiders46.972%
Growth
Revenue Growth0.05%
Earnings Growth0.67%
Estimates
Forward P/E11.00
Forward EPS16.87
Target Mean Price222.29

DCF valuation

Model fair value for DaVita Inc. (DVA)
Result
Sign in to run the valuation for DVA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
7 analysts · consensus Buy · mean target 222.29 USD (low 165.00, high 287.00) · as of 10 Nov 2026
Low 165.00
Mean 222.29
High 287.00
Price 174.56
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

DaVita Inc. Logo DaVita Inc. Analysis (DVA)

United States Health Care Official Website Stock

Is DaVita Inc. a good investment? DaVita Inc. (DVA) is currently trading at 174.56 USD. Market analysts have a consensus price target of 222.29 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 14.05. This relatively low multiple may signal that DaVita Inc. is undervalued compared to historical market norms.

Earnings Schedule: DaVita Inc. is expected to release its next earnings report on Feb. 1, 2027. The market consensus estimate for Forward EPS is 16.87.

Investor FAQ

Does DaVita Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is DaVita Inc.?

DaVita Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 1, 2027. The company currently has a trailing EPS of 13.21.

Company Profile

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Exchange Ticker
NYQ (United States) DVA
FRA (Germany) TRL.F
STU (Germany) TRL.SG
LSE (United Kingdom) 0I7E.L
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Oct. 21, 1997 1.66667
June 16, 2004 1.5
Sept. 9, 2013 2:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion